Return to our Home Page


Technical Resources
Technical Information
Calbiochem Information
Inhibitor Resource
Phosphorylation Dephosphorylation
AKT
AMPK
Aurora Kinase
Cam Kinase
Casein Kinase
Checkpoint Kinase
Cyclin-dependent Kinase
DNA-Dependent Protein Kinase
Glycogen Synthase Kinase
c-Jun N-Terminal Kinase
IP3 Kinase & TGF-b Receptor I Kinase
MAP Kinase
MLCK
PI 3 Kinase
Protein Kinase A
Protein Kinase C
Protein Kinase G
Protein Phosphatase
Protein Tyrosine Kinase
Raf Kinase
Rho Kinase
Sphingosine Kinase

Kinase Kit Resource

Phosphorylation/Dephosphorylation: Rho Kinase (ROCK) Inhibitors
 
Rho kinase (ROCK), a serine/threonine kinase, serves as a target protein for small GTP-binding protein Rho. It serves as an important mediator of numerous cellular functions, including focal adhesions, motility, smooth muscle contraction, and cytokinesis. In smooth muscle, ROCK plays an important role in Ca2+ sensitization and the control of vascular tone. It modulates the level of phosphorylation of the myosin II light chain of myosin II, mainly through inhibition of myosin phosphatase, and contributes to agonist-induced Ca2+ sensitization in smooth muscle contraction.

Rho kinase is found in two forms, ROCK 1 (ROCKb; p160- ROCK) and ROCK 2 (ROCKa). Both ROCK 1 and ROCK 2 contain an amino-terminal catalytic kinase domain, a central coiled-coil domain of about 600 amino acids, and a carboxyl-terminal pleckstrin homology (PH) domain that is split by a cysteine-rich region. Rho/GTP interacts with the C-terminal portion of the central coiled-coil domain and activates the kinase activity of ROCK. Since the ROCK-mediated pathway plays important roles in vascular smooth muscle contraction, cell adhesion, and cell motility, it has gained importance in the pathogenesis of atherosclerosis. ROCK inhibitors are shown to suppress coronary artery spasms. A long-term inhibition of ROCK is reported to block the development of coronary arteriosclerotic lesions.

 
 
Inhibitors: Rho Kinase (ROCK)
 
Inhibitors: Sphingosine Kinase